MaxCyte (NASDAQ:MXCT) vs. Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) Financial Comparison

MaxCyte (NASDAQ:MXCT) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends.

Analyst Ratings

This is a summary of recent ratings and price targets for MaxCyte and Sienna Biopharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	0	2	2	0	2.50
Sienna Biopharmaceuticals	0	0	0	0	0.00

MaxCyte presently has a consensus target price of $7.00, suggesting a potential upside of 360.53%. Given MaxCyte’s stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Sienna Biopharmaceuticals.

Risk and Volatility

MaxCyte has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.

Institutional and Insider Ownership

68.8% of MaxCyte shares are owned by institutional investors. 3.3% of MaxCyte shares are owned by company insiders. Comparatively, 27.2% of Sienna Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MaxCyte and Sienna Biopharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MaxCyte	-125.22%	-22.12%	-19.10%
Sienna Biopharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares MaxCyte and Sienna Biopharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$38.63 million	4.19	-$41.06 million	($0.43)	-3.53
Sienna Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A

Sienna Biopharmaceuticals has lower revenue, but higher earnings than MaxCyte.

Summary

MaxCyte beats Sienna Biopharmaceuticals on 6 of the 10 factors compared between the two stocks.

About MaxCyte

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.